CADTH Canadian Drug Expert Committee Recommendation: Siponimod (Mayzent — Novartis Pharmaceuticals Canada Inc.): Indication: Secondary progressive multiple sclerosis [Internet]
- PMID: 33439598
- Bookshelf ID: NBK566634
CADTH Canadian Drug Expert Committee Recommendation: Siponimod (Mayzent — Novartis Pharmaceuticals Canada Inc.): Indication: Secondary progressive multiple sclerosis [Internet]
Copyright © 2020 Canadian Agency for Drugs and Technologies in Health.
Conflict of interest statement
None
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources